OBJECTIVES: This study assessed recent trends in HIV seroprevalence among injecting drug users in New York City. METHODS: We analyzed temporal trends in HIV seroprevalence from 1991 through 1996 in 5 studies of injecting drug users recruited from a detoxification program, a methadone maintenance program, research storefronts in the Lower East Side and Harlem areas, and a citywide network of sexually transmitted disease clinics. A total of 11,334 serum samples were tested. RESULTS: From 1991 through 1996, HIV seroprevalence declined substantially among subjects in all 5 studies: from 53% to 36% in the detoxification program, from 45% to 29% in the methadone program, from 44% to 22% at the Lower East Side storefront, from 48% to 21% at the Harlem storefront, and from 30% to 21% in the sexually transmitted disease clinics (all P < .002 by chi 2 tests for trend). CONCLUSIONS: The reductions in HIV seroprevalence seen among injecting drug users in New York City from 1991 through 1996 indicate a new phase in this large HIV epidemic. Potential explanatory factors include the loss of HIV-seropositive individuals through disability and death and lower rates of risk behavior leading to low HIV incidence.
OBJECTIVES: This study assessed recent trends in HIV seroprevalence among injecting drug users in New York City. METHODS: We analyzed temporal trends in HIV seroprevalence from 1991 through 1996 in 5 studies of injecting drug users recruited from a detoxification program, a methadone maintenance program, research storefronts in the Lower East Side and Harlem areas, and a citywide network of sexually transmitted disease clinics. A total of 11,334 serum samples were tested. RESULTS: From 1991 through 1996, HIV seroprevalence declined substantially among subjects in all 5 studies: from 53% to 36% in the detoxification program, from 45% to 29% in the methadone program, from 44% to 22% at the Lower East Side storefront, from 48% to 21% at the Harlem storefront, and from 30% to 21% in the sexually transmitted disease clinics (all P < .002 by chi 2 tests for trend). CONCLUSIONS: The reductions in HIV seroprevalence seen among injecting drug users in New York City from 1991 through 1996 indicate a new phase in this large HIV epidemic. Potential explanatory factors include the loss of HIV-seropositive individuals through disability and death and lower rates of risk behavior leading to low HIV incidence.
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: M Marmor; S Titus; C Harrison; E A Cord-Cruz; R E Shore; M Vogler; K Krasinski; D Mildvan; D C Des Jarlais Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-08-15
Authors: D Caussy; S H Weiss; W A Blattner; J French; K P Cantor; H Ginzburg; R Altman; J J Goedert Journal: AIDS Res Hum Retroviruses Date: 1990-12 Impact factor: 2.205
Authors: C Des Jarlais; T Perlis; S R Friedman; T Chapman; J Kwok; R Rockwell; D Paone; J Milliken; E Monterroso Journal: Am J Public Health Date: 2000-07 Impact factor: 9.308
Authors: S J Klein; K Harris-Valente; A R Candelas; M Radigan; M Narcisse-Pean; J M Tesoriero; G S Birkhead Journal: J Urban Health Date: 2001-12 Impact factor: 3.671
Authors: Carey B Maslow; Samuel R Friedman; Theresa E Perlis; Russell Rockwell; Don C Des Jarlais Journal: Am J Public Health Date: 2002-03 Impact factor: 9.308
Authors: Samuel R Friedman; Spencer Lieb; Barbara Tempalski; Hannah Cooper; Marie Keem; Risa Friedman; Peter L Flom Journal: J Urban Health Date: 2005-07-13 Impact factor: 3.671
Authors: Barbara Tempalski; Spencer Lieb; Charles M Cleland; Hannah Cooper; Joanne E Brady; Samuel R Friedman Journal: J Urban Health Date: 2008-11-18 Impact factor: 3.671